Net profit of Unichem Laboratories reported to Rs 30.49 crore in the quarter ended September 2024 as against net loss of Rs 24.49 crore during the previous quarter ended September 2023. Sales rose 11.20% to Rs 462.16 crore in the quarter ended September 2024 as against Rs 415.63 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales462.16415.63 11 OPM %12.452.11 - PBDT61.537.57 713 PBT32.99-21.88 LP NP30.49-24.49 LP Powered by Capital Market - Live News

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live News

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 30 September 2024.Powered by Capital Market - Live News

The Board of Unichem Laboratories will meet on 30 September 2024 to consider and approve integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned subsidiary of Company`s holding company, Ipca Laboratories) into Unichem Pharmaceuticals (USA) Inc. (company`s wholly owned subsidiary) so as to consolidate all the Ipca Group`s USA generics formulations business under one entity.Powered by Capital Market - Live News

The Board of Unichem Laboratories at its meeting held on 08 August 2024 has approved appointment of Sanjay Jain as the ChiefFinancial Officer and Key Managerial Personnel of the Company with effect from 8 August 2024. Powered by Capital Market - Live News